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Abstract: A number of drugs have been approved for the treatment of Alzheimer’s disease 
(AD) and a larger number are being studied as possible therapies. The current mainstays of the 
pharmacotherapy of AD are the cholinesterase inhibitors (donepezil, galantamine, rivastigmine) 
and memantine. They collectively have acceptable tolerability and proven but modest efﬁ  cacy. 
The agents being studied include dietary supplements (eg, vitamin E), herbal preparations 
(eg, Ginkgo biloba), medications approved for other indications (eg, HMG-CoA reductase 
enzyme inhibitors) and research drugs. In this review we discuss in detail the approved agents 
and review a number of the unapproved therapies that are currently available to the practitioner. 
While our era offers much more in the way of therapeutics for AD, it is clear that more work 
still needs to be done.
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Introduction
Alzheimer’s disease (AD) is the commonest type of dementia encountered in older 
patients. While there are a variety of effective non-pharmacological approaches to this 
condition, in this review we will limit ourselves to the pharmacotherapy of AD. We 
will not deal with those agents used primarily for the behavioral and psychological 
symptoms of dementia (eg, antidepressants, antipsychotics). We’ll start with agents 
approved for the indication of AD in Canada. Then, we’ll discuss select agents available 
to physicians that have been (or are being) studied for AD. This will include dietary 
supplements, herbal preparations and prescribed medications where their use for a 
dementia would be considered “off-label” (ie, the practice of prescribing drugs for 
a purpose outside the scope of the drug’s approved indication). We will mention brieﬂ  y 
drugs only available within research studies at the current time.
Agents approved for the treatment of Alzheimer’s 
disease
Cholinesterase inhibitors
The ﬁ  rst cholinesterase inhibitor (ChEI) approved for AD was tacrine in 1993. This 
class of drugs is the most widely prescribed one for the mild to moderate stages of AD. 
Donepezil, galantamine and rivastigmine are the ChEIs that are now most commonly 
used. These drugs are felt to correct the cholinergic deﬁ  cit seen with AD where 
there is the loss of acetylcholine producing neurons in the brain. The ChEIs increase 
acetylcholine concentrations by blocking the action of the enzyme cholinesterase, which 
catalyzes the hydrolysis of acetylcholine into choline and acetic acid. While donepezil, 
galantamine and rivastigmine all inhibit the enzyme acetylcholinesterase, galantamine 
(by binding to an allosteric site on nicotinic receptors) and rivastigmine (through 
inhibition of butrylcholinesterase) have additional mechanisms of action. Their 
signiﬁ  cance remains uncertain.Neuropsychiatric Disease and Treatment 2007:3(5) 570
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Cochrane reviews (Birks 2000; Loy 2005; Birks 2006; 
Birks and Harvey 2006), meta-analyses (Lanctôt et al 2003; 
Ritchie et al 2004; Rockwood 2004; Whitehead et al 2004), 
and qualitative systematic reviews (Clegg et al 2002; Wolfson 
et al 2002; Thompson et al 2004; Kaduszkiewicz et al 2005) 
have all examined the available data on the ChEIs. Cognitive, 
global, functional, behavioral and other outcomes have 
been measured in the randomized controlled trials (RCTs) 
of these agents.
The cognitive measure most often used in AD studies has 
been the Alzheimer’s Disease Assessment Scale – cognitive 
subscale (ADAS-Cog). It includes eleven items (ie, spoken 
language, comprehension of spoken language, recall of 
test instructions, word finding, following commands, 
naming objects, construction – drawings, ideational praxis, 
orientation, word recall and word recognition) and is scored 
out of 70 (higher scores indicate greater impairment). The 
Mini-Mental State Examination (MMSE) is often per-
formed as a secondary cognitive outcome measure. Global 
assessments of subjects in the dementia drug studies have 
often been done using scales such as the Clinicians’ Inter-
view-Based Impression of Change with Caregiver Input 
(CIBIC-Plus). A systematic baseline assessment is done 
that examines the domains ordinarily considered part of 
the clinical evaluation of a patient with dementia. At sub-
sequent visits subjects are graded on a 1–7 scale relative to 
this baseline assessment. One indicates marked improve-
ment, seven marked worsening and four no change. Basic 
and/or instrumental activities of daily living have been 
evaluated using a variety of scales such as the Alzheimer 
Disease Cooperative Study ADL Inventory (ADCS-ADL). 
This is a caregiver rated questionnaire of 23 items. Scores 
can range from 0 to 78. Higher scores indicate better func-
tioning. When examined behavior has most often been 
assessed by the Neuropsychiatric Inventory (NPI). This 
evaluates the research subject for common neuropsychiatric 
disturbances found with AD (ie, delusions, hallucinations, 
agitation, dysphoria, anxiety, apathy, irritability, euphoria, 
disinhibition, aberrant motor behavior, night-time behavior 
disturbances, and appetite and eating abnormalities). Data 
on frequency, severity and caregiver distress are collected. 
The total possible score is 144 with higher scores indicating 
more problems.
The ChEIs have shown consistent, albeit modest, beneﬁ  ts 
of treatment on cognition and global clinical state. After 
treatment for approximately 6 months the advantage seen 
with a ChEI compared to placebo on the 70-point ADAS-Cog 
scale was 2.66 points (95% CI 3.02 to 2.31, p =   0.00001; 
data from 10 studies) and 1.37 points (95% CI 1.13 to 1.61, 
p =   0.00001; data from 9 studies) on the 30-point MMSE 
(Birks 2006). On the CIBIC-Plus scale signiﬁ  cantly more 
of those treated with a ChEI compared to placebo showed 
an improvement (428/1755 or 24% vs 277/1647 or 17%, 
OR 1.56, 95% CI 1.32 to 1.85, p   0.00001) (Birks 2006). 
Improved functional and behavioral outcomes have also 
been seen with active treatment (Trinh et al 2003; Birks 
2006). Less decline (compared to placebo) rather than an 
actual improvement in functional abilities has been the typi-
cal ﬁ  nding. For example, in a 5-month RCT of galantamine 
subjects who received 16 mg/ day of galantamine showed 
on average a 0.7 point decline from baseline on the 78-
point ADCS-ADL while those receiving placebo dropped 
3.8 points (p   0.001) (Tariot et al 2004). As for behavior, on 
the 144-point NPI ChEI therapy was associated with on aver-
age a 2.44 point (95% CI 4.12 to 0.76, p = 0.004) advantage 
compared to placebo (Birks 2006). Based on the available 
evidence, a number of reputable bodies have concluded that 
ChEIs are efﬁ  cacious for mild to moderate AD (Doody, 
Stevens, et al 2001; Patterson et al 2001; Birks 2006; Burns 
and O’Brien 2006; Waldemar et al 2007). The US Food and 
Drug Administration recently (October 13, 2006) approved 
donepezil for the treatment of severe dementia in patients 
with AD. This was based on two RCTs conducted in Sweden 
(Winblad et al 2006) and Japan (unpublished).
The methodological limitations of the published 
studies (eg, reporting more than one outcome without 
correcting for multiple comparisons, absence of ﬁ  nal 
outcome measures on subjects who had withdrawn) 
were speciﬁ  cally noted in one of the systematic reviews 
(Kaduszkiewicz et al 2005). Because of the modest ben-
eﬁ  ts seen coupled with the methodological limitations of 
the studies, the authors questioned the effectiveness of 
these agents. Most other commentators have concluded 
that the likely impact of these methodological concerns 
do not invalidate the ﬁ  ndings of the RCTs. The debate 
continues, though, about the clinical signiﬁ  cance of the 
beneﬁ  ts seen with ChEIs. It has been argued that undue 
emphasis has been placed on statistical tests of signiﬁ  -
cance rather than the practical importance of the beneﬁ  ts 
seen. The controversial AD2000 study was designed to 
determine whether treatment with donepezil produced 
“worthwhile improvements” in socially relevant outcomes 
like nursing home placement (Courtney et al 2005). No 
signiﬁ  cant beneﬁ  ts were seen with donepezil compared 
to placebo in institutionalization rates at the end of the 
trial (42% vs 44% at 3 years; p = 0.4) or in progression Neuropsychiatric Disease and Treatment 2007:3(5) 571
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of disability. Notwithstanding a number of optimistic 
pharmacoeconomic models, doubt remains about the 
cost-effectiveness of ChEIs (Green et al 2005). Recently 
the National Institute for Health and Clinical Excellence 
(NICE) and the Social Care Institute for Excellence 
(SCIE) in the United Kingdom recommended that ChEIs 
be restricted to patients with AD of a moderate severity 
as it was felt that the drugs were cost-effective only in this 
group (National Institute for Health and Clinical Excel-
lence 2006). The manufacturers of donepezil (Eisai and 
Pﬁ  zer) disagreed with this restriction (as do many others) 
and have applied for a judicial review of the process used 
to reach this decision (Anonymous 2006).
If AEs occur with a ChEI, the agent can be either dis-
continued (if the side effects are judged to be disabling 
and/or dangerous) or the dose can be decreased (if the 
side effects are judged to be minor in severity) with an 
option to retry the higher dose after two to four weeks if 
the lower dose is well tolerated. The most common AEs 
encountered with the ChEIs are gastrointestinal symptoms 
such as anorexia, nausea, vomiting and diarrhea (Hogan 
et al 2002; Birks 2006). Gastrointestinal AEs in the RCTs 
were more likely to occur at the commencement of therapy 
(or when the dosage was increased), at the higher dose 
ranges and tended to be transient. They appeared to be more 
common with rivastigmine than donepezil (Birks 2006). 
Slower titration and ensuring that rivastigmine is taken with
food decreases the risk of gastrointestinal side effects. 
A transdermal rivastigmine patch is being developed in 
the expectation that it will show similar efﬁ  cacy to the oral 
form but with fewer AEs (Priano et al 2006). If nausea and/ 
or vomiting occur with the use of a ChEI, the prescribing 
clinician should review how the medication is being taken 
(eg, dose, frequency, with or without food, evidence of 
an unintentional over-dose) and consider modifying the 
prescription (eg, lower the dose), reassigning responsibility 
for administration (eg, if the patient cannot correctly follow 
the directions given), changing the directions given (eg, 
take with food) or stopping the agent. While anti-emetics 
can be used for nausea and/or vomiting, a number of them 
(eg, dimenhydrinate, prochlorperazine) have anticholinergic 
properties. The concurrent use of anticholinergics and 
ChEIs might be associated with both worse cognitive 
outcomes (Lu and Tune 2003) and a lower likelihood of 
persisting with ChEI therapy (Kogut et al 2005). Weight 
loss did occur during the RCTs of the ChEIs but a study 
directly addressing this concern found that there wasn’t an 
increased risk for weight loss (compared to patients with 
AD not receiving a ChEI) with long-term use of these agents 
(Gillette-Guyonnet et al 2005).
Dizziness has been reported with donepezil, galantamine 
and rivastigmine. If disabling, the ChEI could be stopped 
or the dose reduced. Syncope, while rare, has been associ-
ated with the use of these agents. The loss of consciousness 
might arise from an arrhythmia. It is well known that ChEIs 
can lead to sinus bradycardia (Hogan et al 2002). Case 
reports of syncope from a complete atrioventricular block 
with ventricular tachyarrhythmia (Newby et al 2004) and 
the cardioinhibitory type of carotid sinus hypersensitivity 
have been reported with donepezil (Suleyman et al 2006). 
Noninvasive evaluation can usually identify the probable 
cause of syncope in AD patients being treated with a ChEI 
(Bordier et al 2005). Management could include the implan-
tation of a pacemaker, depending on what is found (Bordier 
et al 2003). The presence of unexplained syncope would be 
a contraindication to the use of a ChEI.
Donepezil has been associated with sleep disturbances, 
vivid dreams/nightmares and hypnopompic hallucinations 
(Hogan et al 2002). There is a higher likelihood of insom-
nia occurring with the higher doses of donepezil (Birks and 
Harvey 2006). Rivastigmine and galantamine appear to be 
less likely to cause sleep disturbances. Management options 
for this problem would include switching to another ChEI.
An interesting potential problem with the ChEIs is that 
of a prescribing cascade. Here an adverse reaction to one 
drug leads to the prescription of a second drug to deal with 
the AE. For example, the use of ChEIs was associated with 
an increased risk of receiving a new prescription for an 
anticholinergic drug to manage urinary incontinence (Gill 
et al 2005). The use of the anticholinergic agent in this setting 
may represent the tail end of a prescribing cascade. Another 
example would be the higher use of hypnotics in AD patients 
treated with donepezil (Stahl et al 2003). Clinicians should 
always consider the possible contributing role of ChEIs to 
new or worsening medical concerns in treated patients. The 
use of a second agent to treat an AE will expose the patient to 
the potential risk of an adverse drug – drug or drug – disease 
interaction.
Indirect comparisons of the relative efﬁ  cacy and toler-
ability of the ChEIs across clinical trials must be done 
with great caution as they are based on the questionable 
assumption that the trials were done in similar settings and 
on equivalent populations using comparable measures of 
efﬁ  cacy and toxicity (Ioannidis 2006). The published trials 
that directly compared one ChEI to another had serious 
methodological limitations and/or showed no signiﬁ  cant Neuropsychiatric Disease and Treatment 2007:3(5) 572
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differences in the primary outcome measures selected (Hogan 
et al 2004; Bullock et al 2005; Birks 2006). It is generally 
felt that the ChEIs have similar efﬁ  cacy. Selection of which 
ChEI to use should be based on adverse effect (AE) proﬁ  le, 
ease of use, familiarity with the agents and/or beliefs about 
the importance of the differences in their pharmacokinetics 
and other mechanisms of action.
Because of an unsatisfactory response and/or intolerable 
AEs, a patient on one ChEI may want to “switch” to a dif-
ferent one (Auriacombe et al 2002; Bullock and Connolly 
2002; Emre 2002; Gauthier et al 2003; Bartorelli et al 2005; 
Sadowsky et al 2005; Wilkinson and Howe 2005; Dantoine 
et al 2006). If a switch is being made on the basis of an unsat-
isfactory response, patients can abruptly discontinue the ﬁ  rst 
ChEI and start taking the second agent quickly afterwards 
(eg, the next day) without a washout period. They would 
start at the usual starting dose of the second agent followed 
by upward titration at the recommended rate. The approach 
would be different if the change is being made because of AEs. 
After stopping the ﬁ  rst agent the second one would generally 
not be started until a week or two after resolution of the AE. 
A number of open-label, time-series studies on switching 
have been done and they indicate that it can be safely done 
(Auriacombe et al 2002; Gauthier et al 2003; Bartorelli et al 
2005; Wilkinson and Howe 2005; Dantoine et al 2006). While 
beneﬁ  ts have been claimed, the available studies would have 
to be viewed as methodologically weak and not convincing. 
None have looked at switching to donepezil. A presentation 
at the 7th International Conference on Alzheimer’s and 
Parkinson’s Disease indicated that switching from donepezil 
to memantine was well tolerated whether it was done abruptly 
(donepezil discontinued one day with memantine started 
the next day and titrated up to 20 mg/d over three weeks) 
or gradually (donepezil dropped from 10 mg/d to 5 mg/d 
for two weeks before stopping; memantine then started and 
titrated upwards to 20 mg/d over three weeks). There is the 
potential of harm with switching. It can be associated with 
deterioration in the patient’s condition and there has been a 
case report of a fatality from aspiration pneumonia in a patient 
switched from donepezil to rivastigmine (Taylor et al 2002). 
The decision to make a switch should be based on the judg-
ment of the prescribing physician about the relative beneﬁ  ts 
and risks of making a change and the wishes of the patient 
(or their proxy). In routine practice switching from one ChEI 
to another appears to be a relatively rare ( 5% of treated 
patients) event (Dybicz et al 2006).
An area of continuing uncertainty is when to stop a 
ChEI. These decisions should be individualized and based 
on the balance between beneﬁ  ts and harm for the patient. 
Stopping to see if there was in fact a treatment beneﬁ  t, 
which becomes evident during the washout period, has 
become contentious. Studies suggest that interrupting 
therapy for a number of weeks can result in cognitive and/ 
or functional losses that cannot be fully recaptured – even 
if the ChEI is restarted (Doody, Geldmacher et al 2001). 
Notwithstanding this, medications for the treatment of the 
cognitive and functional manifestations of AD should be 
discontinued when:
1.  The patient and/or their proxy decision maker decides to 
stop;
2.  The patient refuses to take the medication;
3.  The patient is sufﬁ  ciently nonadherent with the medica-
tion that continued prescription of it is viewed as futile 
and it is not possible to establish a system for the admin-
istration of the medication to rectify the problem;
4.  There is no response to therapy after a reasonable trial 
(eg, 3–6 months);
5.  The patient experiences intolerable side effects;
6.  The co-morbidities of the patient make continued use 
of the agent either unacceptably dangerous or futile (eg, 
terminally ill); or
7.  The patient’s dementia has progressed to a stage where 
there is no signiﬁ  cant beneﬁ  t from continued therapy.
If therapy is stopped, patients should be carefully moni-
tored and if there is evidence of a signiﬁ  cant decline in their 
cognitive status, functional abilities or the development/ 
worsening of behavioural challenges consideration should 
be given to quickly re-instating therapy.
Memantine
Neuronal excitotoxicity from glutamatergic neurotrans-
mission is felt to be involved in the pathogenesis of AD. 
Memantine is a low to moderate afﬁ  nity uncompetitive 
antagonist to the glutamatergic N-methyl-D-aspartic acid 
(NMDA) receptors. It inhibits the prolonged inﬂ  ux of 
Ca2+ ions that forms the basis of neuronal excitotoxicity. 
Because of its low afﬁ  nity memantine allows for normal 
functioning of the receptor as it can still be activated by 
the relatively high concentrations of glutamate released 
immediately following depolarisation of presynaptic 
neurons. There is also some evidence from cell studies 
that memantine might decrease tau phosphorylation and 
thereby inhibit neurofibrillary degeneration (Chohan 
et al 2006).
A Cochrane Systematic Review concluded that there 
was a small beneﬁ  cial effect of memantine at six months Neuropsychiatric Disease and Treatment 2007:3(5) 573
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in moderate to severe AD and a marginal beneﬁ  t in those 
with mild to moderate disease (McShane et al 2006). A 
RCT published subsequent to the Review reported that 
the agent was safe and effective for mild to moderate 
AD (Peskind et al 2006). Notwithstanding this publica-
tion, memantine has generally been recommended as an 
option for patients with moderate to severe stages of AD 
only (Farlow and Cummings 2007; Schmitt et al 2007, 
Waldemar et al 2007) as the treatment effects seen with 
mild to moderate AD have not been consistently signiﬁ  cant 
(Cosman et al 2007).
While memantine can be used as monotherapy for 
AD, it has a different mechanism of action than the 
ChEIs. Combination therapy with a ChEI would seem to 
be a rational option. An adult rat study, though, showed 
that co-administration of high doses of memantine 
(10–30 mg/kg) and donepezil (5–10 mg/kg) given intraperi-
toneally potentiated a NMDA antagonist type neurotoxic 
reaction in the brains of the study animals (Creeley et al 
2006). The clinical signiﬁ  cance of this ﬁ  nding is uncertain. 
Published human studies of combination therapy have 
been favorable. A RCT showed additional beneﬁ  t when 
memantine was added to chronic donepezil therapy in 
patients with moderate to severe AD (Tariot et al 2004). 
When treatment response was deﬁ  ned as stabilization on 
individual outcome measures the combination resulted in 
signiﬁ  cantly higher response rates than donepezil alone 
with the number needed to treat (NNT) ranging from 8–10 
(van Dyck et al 2006). Two open-label studies found that 
the combination of rivastigmine and memantine was both 
safe and possibly beneﬁ  cial (Dantoine et al 2006; Riepe 
et al 2006). The combination of galantamine and memantine 
also appears to be well tolerated (Grossberg et al 2006). 
The available human data indicates that combining meman-
tine with a ChEI is safe and may lead to additional beneﬁ  ts 
for patients with moderate to severe AD.
As with the ChEIs there is uncertainty about the 
clinical signiﬁ  cance of the beneﬁ  ts seen with this agent. 
In 2005 the Canadian Expert Drug Advisory Committee 
(CEDAC) recommended that memantine not be listed on 
the formularies of the Canadian government-funded drug 
beneﬁ  t programs on the grounds that the clinical impor-
tance of the changes seen with memantine has not been 
established. The Committee was not convinced by the 
pharmacoeconomic model submitted by the manufacturer. 
Likewise the National Institute for Health and Clinical 
Excellence in the United Kingdom has recommended that 
memantine not be offered to those with AD unless it was 
part of a well designed clinical trial (National Institute for 
Health and Clinical Excellence 2006).
Select agents not approved for the 
treatment of Alzheimer’s disease
Antioxidants
Oxidative stress (a harmful condition that occurs when there 
is an excess of free radicals, a decrease in antioxidant levels, 
or both) may play a role in the pathogenesis of AD. Vitamin E 
is an antioxidant that has been studied as a possible therapy 
for AD. A 2-year, randomized, placebo-controlled trial of 
the effects of selegiline (10 mg a day), alpha-tocopherol 
(vitamin E, 2000 IU a day) or both on subjects with moderate 
AD was conducted. As their primary outcome measure the 
investigators looked at the time till the occurrence of any of 
the following: death, institutionalization, loss of the ability 
to perform basic activities of daily living, or severe dementia 
(Sano et al 1997). In their unadjusted analyses, there were 
no statistically signiﬁ  cant differences in outcome among 
the four groups. In analyses that included the base-line score 
on the MMSE as a covariate, those on vitamin E showed a 
signiﬁ  cant (p = 0.001) delay in the time to the occurrence of 
the primary outcome. The estimated increase was 230 days. 
There was no apparent beneﬁ  t on either of the two cognitive 
measures (ADAS-Cog, MMSE) they used. For the speciﬁ  c 
outcome of institutionalization vitamin E therapy showed a 
signiﬁ  cant treatment effect. In a RCT of subjects with amnes-
tic Mild Cognitive Impairment (which is felt be many to be 
a precursor of AD) participants were assigned to 2000 IU of 
vitamin E daily, 10 mg of donepezil daily, or placebo and 
then followed for up to three years (Petersen et al 2005). The 
primary outcome was progression to possible or probable 
AD. No beneﬁ  t from vitamin E was found. There is insuf-
ﬁ  cient evidence of efﬁ  cacy for vitamin E in the treatment of 
AD to justify its use (Tabet et al 2000). Of additional concern 
is the recent ﬁ  nding that high dose vitamin E (400+ IU daily) 
supplementation is associated with an increased mortality 
risk (Miller et al 2005).
The purported beneﬁ  cial actions of Ginkgo biloba for 
dementia include vasodilatation, reduced blood viscosity, 
modifications in neurotransmitter systems and reduc-
ing levels of oxygen free radicals (Birks et al 2002). A 
Cochrane Review of the agent concluded that it was both 
safe and promising. Concerns were expressed about the 
soundness of the earlier studies. The more methodologically 
rigorous trials have shown inconsistent results (Birks et al 
2002). Since the publication of the Review two placebo-
controlled trials of Ginkgo for AD have appeared. One was Neuropsychiatric Disease and Treatment 2007:3(5) 574
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interpreted as being positive (Kanowski and Hoerr 2003) 
while the other showed no signiﬁ  cant beneﬁ  t (van Donigen 
et al 2003). An underpowered six-month study compared 
Ginkgo and donepezil (Mazza et al 2006). While the authors 
concluded that donepezil and Ginkgo had similar efﬁ  cacy, 
the study was too small to permit such a conclusion. It is 
well tolerated. In the RCTs of Ginkgo there were fewer 
reported withdrawals because of AEs than what was seen 
with the ChEIs (Kurz et al 2006). There might be a small 
risk of bleeding. A number of case reports have described a 
temporal association between using Ginkgo and a bleeding 
event (Bent et al 2005). In most of these cases other risk 
factors for bleeding were identiﬁ  ed. Patients using Ginkgo, 
particularly those with known bleeding risks (eg, concur-
rent use of warfarin or antithrombotics), should be warned 
about a possible increase in the chances of a hemorrhage. 
Additional concerns about Ginkgo include variability in the 
quality of the agents available for purchase (Garrard et al 
2003) and the excessive claims made for its effectiveness 
(Morris and Avorn 2003). In other words, “Let the buyer 
beware” (caveat emptor). There is currently insufﬁ  cient 
evidence to recommend either for or against the use of 
Ginkgo biloba in AD.
Idebenone is related to coenzyme Q10, an intermediate 
in the oxidative phosphorylation pathway. While it has a 
number of potential mechanisms of action it does appear to 
be an antioxidant, inhibiting lipid peroxidation by scaveng-
ing free radicals. A 1-year RCT of 536 subjects with prob-
able AD compared three doses of the agent with a placebo 
group. There was no signiﬁ  cant beneﬁ  t seen with treatment 
in the pre-speciﬁ  ed four-group analysis. When all three 
idebenone dosages were grouped together and compared 
with placebo there was a small (1.9 points) difference on the 
ADAS-Cog that was statistically signiﬁ  cant (p = 0.02). No 
signiﬁ  cant beneﬁ  ts were seen on the other outcome measures. 
The authors concluded that the effect on the ADAS-Cog 
was of insufﬁ  cient magnitude to be clinically signiﬁ  cant 
(Thal et al 2003).
Folic acid, vitamin B6 and vitamin B12
In the Framingham Study cohort a higher plasma homocys-
teine level was found to be a risk factor for the development 
of AD (Seshadri et al 2002). The risk of developing AD 
nearly doubled with a plasma homocysteine level greater than 
14 μmol per liter. Possible mechanisms for the association 
include accelerated development of atherosclerosis, neuronal 
excitotoxicity from the activation of NMDA receptors, 
hypomethylation, increases in oxidative stress and increases 
in ß-amyloid toxicity. Most elevations in homocysteine are 
felt to be from inadequate folate, vitamin B12, and/or vitamin 
B6 intake. Data on the effects of folic acid, vitamin B6 and/ 
or vitamin B12 on patients with AD are limited. No cognitive 
beneﬁ  t from folic acid (with or without vitamin B12) has been 
seen in demented individuals (Malouf et al 2003). No trials 
of vitamin B6 involving people with dementia have been 
done (Malouf and Grimley Evans 2003). Finally, two RCTs 
of people with dementia and low serum vitamin B12 levels 
treated with Vitamin B12 supplementation found no evi-
dence of a signiﬁ  cant treatment effect on cognitive function
(Malouf and Aerosa 2003). Though a low risk intervention, 
the routine administration of folate, B6 and/or B12 supple-
ments to individuals suffering from AD cannot be endorsed 
at the present time (Balk et al 2007). Those with documented 
deﬁ  ciences, though, should be treated.
Anti-inﬂ  ammatory agents
Inﬂ  ammation is felt to be part of the pathological cascade 
that leads to AD. While there is epidemiological evidence 
that patients on anti-inﬂ  ammatory agents have a reduced 
incidence of AD (McGeer et al 1996; Wolfson et al 2002), 
the RCTs employing anti-inﬂ  ammatory drugs as therapy 
for AD have been disappointing to date. An early study of 
indomethacin did show some promise but AEs were common 
(Rogers et al 1993) and additional studies were not done. The 
use of this agent cannot be recommended for AD (Tabet and 
Feldman 2002). Studies that examined celecoxib, diclofenac, 
naproxen and rofecoxib have been negative (Scharf et al 
1999; Aisen et al 2003; Reines et al 2004; Firuzi and Praticò 
2006). At the present time the use of a NSAID for the 
treatment of AD cannot be recommended.
NSAIDs may work by mechanisms other than cyclooxy-
genase (COX) inhibition. Some (eg, diclofenac, sulindac, 
indomethacin, ﬂ  urbiprofen, ibuprofen) but not all NSAIDs 
have been found to affect Aβ deposition and metabolism 
(Imbimbo 2004). It is possible that the negative NSAID trials 
to date may be due to selecting the wrong NSAID.
Flurizan™ is the R-enantiomer of flurbiprofen and 
appears to lower Aβ42 production by selectively modulating 
γ-secretase activity, shifting the metabolism of amyloid 
precursor protein towards the production of shorter, less toxic 
fragments. It is felt to lack signiﬁ  cant COX inhibiting activity 
and has little in the way of gastrointestinal AEs. Promising 
results have been obtained and a Phase III clinical trial is 
currently underway.
A study of prednisone (20 mg for one month then 10 mg 
for one year) in 132 patients failed to show any signiﬁ  cant Neuropsychiatric Disease and Treatment 2007:3(5) 575
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beneﬁ  t (Aisen et al 2000). A RCT of hydroxychloroquine 
was also negative (van Gool et al 2001).
Inhibitors of the HMG-CoA reductase 
enzyme
In vitro and animal studies have demonstrated that treatment 
with cholesterol-lowering drugs reduces the production of 
Aβ. Some of the large RCTs of inhibitors of the HMG-CoA 
reductase enzyme (ie, “statins”) have included secondary 
cognitive outcomes. The MRC/BHF Heart Protection Trial 
(simvastatin was the agent used) found no beneﬁ  t with active 
treatment on the likelihood of either cognitive decline or 
developing a dementia (Heart Protection Study Collaborative 
Group 2002). The PROspective Study of Pravastatin in the 
Elderly at Risk (PROSPER) trial also could not demonstrate 
any cognitive beneﬁ  t with pravastatin (Shepherd et al 2002). 
Simvastatin was examined in a 26-week study of individuals 
with mild to moderate AD. With active treatment there was a 
small but signiﬁ  cant reduction of Aβ40 in the cerebrospinal 
ﬂ  uid of mild AD subjects. The mean MMSE score in the 
placebo group dropped from 17.1 to 14.4. In the simvastatin 
group, the mean MMSE score declined marginally from 17.8 
to 17.2. At the end of the treatment period the difference 
in MMSE scores between the two groups was signiﬁ  cant 
(p   0.02) (Simons et al 2002). A 12 month placebo 
controlled pilot trial of atorvastatin 60 mg in 71 patients 
with mild to moderate AD showed statistically signiﬁ  cant 
improvement on the ADAS-Cog at 6 months and a positive 
trend at 12 months (Sparks et al 2005). A phase III trial is 
currently on-going. There was no evidence of any signiﬁ  cant 
interaction between statins and galantamine in a small study 
(Winblad et al 2007). Though a promising area, HMG-CoA 
reductase enzyme inhibitors are not recommended for the 
treatment of AD at the present time.
Estrogen and androgen hormone therapy
A Cochrane review examined the effect of hormone replace-
ment therapy on cognition in women suffering from a 
dementia. Five double-blind RCTs were examined in detail. 
Short-lived and clinically insigniﬁ  cant beneﬁ  cial effects 
with conjugated equine estrogens (CEE) were found on 
the MMSE (CEE 0.625 mg/d only), Trail-Making Test-B 
(CEE 0.625 mg/d only) and digit span backwards (CEE 
1.25 mg/d only). Cued delayed recall of a word list was 
improved after two months of treatment with transdermal 
diestradiol. Control subjects did significantly better on 
delayed recall (one month), ﬁ  nger tapping (12 months) and 
on the Clinical Dementia Rating scale. After correction for 
multiple testing only the short-term effect of transdermal 
estrogen remained statistically signiﬁ  cant (Hogervorst et al 
2006). Hormone replacement therapy (estrogens combined
with a progestagen) or estrogen replacement therapy (estrogen 
alone) is not recommended for the cognitive impairments of 
women with AD.
Androgens can inﬂ  uence brain function directly through 
androgen receptors or indirectly through estradiol (testos-
terone is converted to estradiol by aromatase) (Henderson 
and Hogervorst 2004). In vitro and animal studies indi-
cate that androgen depletion is associated with higher 
brain levels of beta-amyloid, hyperphosporylation of tau 
protein and decreased neuronal survival after exposure to 
a toxin (Almeida and Flicker 2003; Ramsden et al 2003; 
Henderson and Hogervorst 2004). Studies of healthy older 
men suggest that therapy with testosterone has a weak and 
inconsistent association with better visuospatial and memory 
scores on testing (Almeida and Flicker 2003). Some but 
not all studies have shown an association between reduced 
testosterone levels and a diagnosis of AD (Moffat et al 
2004). Two small intervention studies that included subjects 
with AD have been done. Ten hypogonadal nursing home 
patients with AD were randomized to either IM testosterone 
enanthate 200 mg every two weeks or placebo (Tan and Pu 
2003). Unblinded assessments at three, six and none months 
showed improvements on the ADAS-Cog, MMSE and the 
Clock Drawing Test. One patient became aggressive and 
developed hypersexual behavior. No other problems were 
noted. The second study was a randomized, double-blind, 
placebo-controlled six-week trial that examined the effects 
of weekly IM injections of 100 mg of testosterone enanthate 
on subjects with Mild Cognitive Impairment or AD (a total 
of 15 subjects with AD were enrolled) (Cherrier et al 2005). 
Improvements in spatial memory/ability and verbal memory 
were seen with testosterone therapy. No adverse effects were 
encountered. Both groups of researchers felt that additional 
studies were required. There is insufﬁ  cient evidence to 
recommend the use of androgens (eg, testosterone) to treat 
men with AD.
Other agents
A large number of compounds with diverse proposed 
mechanisms of action are being or have been tested as 
potential therapies for AD. A partial listing (in alphabetical 
order) would include: Aβ aggregation inhibitors; acetyl-
L-carnitine; active or passive beta-amyloid immunization; 
Alzhemed™; ampakines; 3-amino-1-propanesulfonic 
acid (3APS); aniracetam; BMY21,502; bapineuzumab; Neuropsychiatric Disease and Treatment 2007:3(5) 576
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besipiridine; cerebrolysin; clioquinol; cytidinediposphocholine 
(CDP-choline); D-cycloserine; DGAVP; dapsone; dehydro-
epiandrosterone; dimebon; doxycycline and rifampin; eryth-
ropoietin; extract of Melissa ofﬁ  cinalis; gamma-aminobutyric 
acid (GABA) receptor anatagonists; garlic; γ-secretase inhibi-
tors; glycogen synthase kinase inhibitors; growth hormone 
releasing hormone; huperzine A; Hydergine™; ispronicline; 
lecozotan; lethicin; lithium carbonate; melatonin; milacemide; 
neramexane; muscarinic receptor agonists; nerve growth factor 
(NGF) gene therapy and mimics; nicergoline; nicotinic recep-
tor modulators; nicotine; nimodipine; paclitaxel; peroxisome 
proliferator-activated receptor (PPAR)-γ agonists; phosphatidyl 
serine; phosphodiesterase inhibitors; physostigmine; piracetam; 
propentofylline; rosiglitazone; selegiline; serotonin receptor 
anatagonists; velnacrine; and, vinpocetine.
The studies that have been completed have yielded nega-
tive or inconclusive results. None of these agents have been 
approved for the treatment of AD in Canada. Their use can 
not be recommended at this time except as part of a well-
designed drug trial.
Conclusion
With so many drugs being looked at the optimist in me is 
hopeful for the future, the cynic feels that the large number 
being considered indicates that nothing truly works and the 
realist reﬂ  ects that after the modern era of AD pharmaco-
therapy opened over twenty years ago in 1986 with the New 
England Journal of Medicine report on tetrahydroamino-
acridine (Summers et al 1986) we are still left with a very 
limited armentarium. The somewhat disappointing results 
seen to date might reﬂ  ect the degree of brain damage that has 
occurred before the drugs are used. It is estimated that in AD 
neurodegeneration starts 20–30 years before the appearance 
of the ﬁ  rst clinical symptoms (Goedert and Spillantini 2006). 
It might be a question of too little and too late.
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